⌘K
Loading ticker…
Ardelyx, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ardelyx, Inc. (ARDX) has a 3-month relative strength percentile of 36 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.2%, relative volume 5.06×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
36 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ARDX is in a stage 3 topping pattern, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -9.5% / -9.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
ARDX is held by 6 ETFs as of Mar 2026. Top owner: XBI at 0.62% weight, $46M notional. Top 3 carry $125M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.62% | $46M |
| VTIVanguard Total Stock Market ETF | 0.00% | $44M |
| IWMiShares Russell 2000 ETF | 0.05% | $35M |
| VXFVanguard Extended Market ETF | 0.02% | $16M |
| IWOiShares Russell 2000 Growth ETF | 0.10% | $12M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARDX Jan avg: 20.31% median: 18.81% win: 100% σ: 18.92% n: 4 2022-04-12 → 2026-05-29 | ARDX Feb avg: -2.44% median: -0.85% win: 25% σ: 9.03% n: 4 2022-04-12 → 2026-05-29 | ARDX Mar avg: 6.93% median: -8.47% win: 25% σ: 40.08% n: 4 2022-04-12 → 2026-05-29 | ARDX Apr avg: -2.20% median: -6.89% win: 40% σ: 10.56% n: 5 2022-04-12 → 2026-05-29 | ARDX May avg: -15.22% median: -20.24% win: 20% σ: 16.33% n: 5 2022-04-12 → 2026-05-29 | ARDX Jun avg: 1.55% median: 4.15% win: 75% σ: 8.28% n: 4 2022-04-12 → 2026-05-29 (current) | ARDX Jul avg: 4.40% median: 12.19% win: 75% σ: 20.15% n: 4 2022-04-12 → 2026-05-29 | ARDX Aug avg: 26.32% median: 23.58% win: 100% σ: 20.05% n: 4 2022-04-12 → 2026-05-29 | ARDX Sep avg: 4.86% median: 3.63% win: 50% σ: 17.19% n: 4 2022-04-12 → 2026-05-29 | ARDX Oct avg: 4.51% median: 3.40% win: 50% σ: 17.57% n: 4 2022-04-12 → 2026-05-29 | ARDX Nov avg: 5.29% median: 5.38% win: 50% σ: 10.56% n: 4 2022-04-12 → 2026-05-29 | ARDX Dec avg: 23.28% median: 19.00% win: 75% σ: 34.96% n: 4 2022-04-12 → 2026-05-29 |